Region-specific astrogliosis in brains of mice heterozygous for mutations in the neurofibromatosis type 1 (Nf1) tumor suppressor

Brain Research

Volumn 816, Issue 1, 1999, Pages 111-123

  Rizvi, Tilat A ^a   Akunuru, Shailaja ^a   De Courten Myers, Gabrielle ^b   Switzer III, Robert C ^c   Nordlund, Michael L ^a   Ratner, Nancy ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c NeuroScience Associates   (United States)

Author keywords

Astrocyte; Gliosis; Learning disability; Mouse; Neurofibromatosis; Neurofibromin; NF1; Ras

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; NEUROFIBROMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; ASTROCYTOSIS; CELL SIZE; CONTROLLED STUDY; GENE MUTATION; HIPPOCAMPUS; IMMUNOBLOTTING; LEARNING DISORDER; MALE; MOUSE; NEUROFIBROMATOSIS; NONHUMAN; NUCLEUS ACCUMBENS; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

ANIMALS; ASTROCYTES; BRAIN; CEREBELLUM; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; GENES, NEUROFIBROMATOSIS 1; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIOSIS; HETEROZYGOTE; HIPPOCAMPUS; MALE; MICE; MICE, INBRED C57BL; MICE, NEUROLOGIC MUTANTS; MUTATION; NERVE DEGENERATION; NUCLEUS ACCUMBENS; PERIAQUEDUCTAL GRAY; THALAMUS; TUBULIN;

EID: 0033573694     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(98)01133-0     Document Type: Article

References (57)

1. D'Adamo P., Menegon A., Lo Nigro C., Grasso M., Gulisano M., Tamanini F., Bienvenu T., Gedeon A.K., Oostra B., Wu S.K., Tandon A., Valtorta F., Balch W.E., Chelly J., Toniolo D. Mutations in GDI1 are responsible for X-linked non-specific mental retardation. Nature Genet. 19(2):1998;134-139.
2. Aoki S., Barkovich A.J., Nishimura K. Neurofibromatosis types 1 and 2: cranial MR findings. Radiology. 172:1989;527-534.
3. Black J.E., Sontheimer, Waxman S.G. Spinal cord astrocytes in vitro: phenotypic diversity and sodium channel immunoreactivity. Glia. 7:1993;272-285.
4. Brannan C.I., Perkins A.S., Vogel K.S., Ratner N., Nordlund M.L., Reid S.W., Buchberg A.M., Jenkins N.A., Parada L.F., Copeland N.G. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes and Development. 8:1994;1019-1029.
5. Casanova M.F., Stevens J.R., Kleinman J.E. Astrocytosis in the molecular layer of the dentate gyrus: a study in Alzheimer's disease and schizophrenia. Psychiatric. Res. 35:1990;149-166.
6. C.A. Crowe, W.J. Schull, J.V. Neel, A clinical, pathological and genetic study of multiple neurofibromatosis, Springfield, IL, Charles C. Thomas, 1956, pp. 1-181.
7. Daston M.M., Scrable H., Nordlund M., Sturbaum A.K., Nissen L.M., Ratner N. The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells, and oligodendrocytes. Neuron. 8:1992;415-428.
8. Daston M., Ratner N. Neurofibromin, a predominantly neuronal GTPase activating protein in the adult, is ubiquitously expressed during development. Dev. Dynamics. 195:1992;216-226.
9. J.S. De Olmos, S.O.E. Ebbesson, L. Heimer, Silver methods for the impregnation of degenerating axoplasm, in: L. Heimer, M.J. Robards (Eds.), Neuroanatomical Tract-tracing Methods, Plenum Press, New York, 1981, pp. 117-170.
10. DiMario F.J., Ramsby G., Greenstein R., Langshur S., Dunham B. Neurofibromatosis type 1: magnetic resonance imaging findings. Child Neurol. 8:1993;32-39.
11. DiPaolo D.P., Zimmerman R.A., Rorke L.B., Zackai E.H., Bilanuk L.T., Yachnis A.T. Neurofibromatosis type 1: pathologic substrate of high signal intensity foci in the brain. Neuroradiology. 195:1995;721-724.
12. Duffner P.K., Cohen M.E., Seidel F.G., Shucard D.W. The significance of MRI abnormalities in children with neurofibromatosis. Neurology. 39:1989;373-378.
13. Dunn D.W., Roos K.L. Evaluation of learning difficulties and incoordination in neurofibromatosis type 1. Neurofibromatosis. 2:1989;1-5.
14. Eddleston M., Mucke L. Molecular profile of reactive astrocytes implication for their role in neurologic disease. Neuroscience. 54:1993;15-36.
15. L.F. Eng, Y.L. Lee, Intermediate filaments in astrocytes, in: H. Kettenman, B.R. Ransom (Eds.), Neuroglia, Oxford University Press, 1995, pp. 650-667.
16. L.F. Eng, Regulation of glial intermediate filaments in astrogliosis, in: M.D. Norenberg, L. Hertz, A. Schousboe (Eds.), Biochemical Pathology of Astrocytes, Liss, New York, 1988, pp. 79-90.
17. Ferner R.E., Hughes R.A.C., Wenman J. Intellectual impairment in NF1. J. Neurol. Sci. 138:1996;125-133.
18. Giordano M.J., Mahadeo D.K., He Y.Y., Geist R.T., Hsu C., Gutman D.H. Increased expression of the neurofibromatosis 1 (NF1) gene product, neurofibromin, in astrocytes in response to cerebral ischemia. J. Neurosci. Res. 43(2):1996;246-253.
19. Golubic M., Roudebush M., Dobrowolski S., Wolfman A., Stacey D.W. Catalytic properties, tissue distribution and intracellular distribution of neurofibromin. Oncogene. 7:1992;2151-2159.
20. Guo H.-F., The I., Hannan F., Bernards A., Zhong Y. Requirement of Drosophila NF1 for activation of adenlyl cyclase by PACAP38-like neuropeptides. Science. 276:1997;795-798.
21. Gutmann D., Aylsworth A., Varey J., Korf B., Marks J., Pyeritz R., Rubenstein A., Viskochil D. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. J. Am. Med. Assoc. 278:1997;51-57.
22. Hewett S.J., Choi D.W., Gutmann D.H. Expression of the neurofibromatosis 1 (NF1) gene in reactive astrocytes in vitro. NeuroReport. 6(11):1995;1565-1568.
23. Hofman K.J., Harris E.L., Bryan N., Denckla M.B. Neurofibromatosis type 1: the cognitive phenotype. J. Pediatrics. 124:1994;S1-S8.
24. Huson S.M., Compston D.A.S., Clark P., Harper P.S. A genetic study of von Recklinghausen neurofibromatosis in South East Wales: I. Prevalence, fitness, mutation, rate and effect of parental transmission on severity. J. Med. Genetics. 26:1989;704-711.
25. Huson S.M., Harper P.S., Compston D.A.S. Von Recklinghausen neurofibromatosis. A clinical and population study in South-East Wales. Brain. 111:1988;1355-1381.
26. Huynh D.P., Lin C.T., Pulst S.M. Expression of neurofibromin, the neurofibromatosis 1 gene product: studies in human neuroblastoma cells and rat brain. Neurosci. Lett. 143:1992;233-236.
27. Jacks T., Shih T.S., Schmitt E.M., Bronson R.T., Bernards A., Weinberg R.A. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nature Genet. 7:1994;353-361.
28. Jorgensen O.S., Brooksbank B.W.L., Balazs R. Neuronal plasticity and astrocytic reaction in Down Syndrome and Alzheimer disease. J. Neurol. Sci. 98:1990;63-79.
29. Kim H., Ling B., Ratner N. NF1 deficient mouse Schwann cells are angiogenic, invasive and can be induced to hyperproliferate: reversion of some phenotypes by an inhibitor farnesyl protein transferase. Mol. Cell. Biol. 17:1997;862-872.
30. Kim H., Rosenbaum T., Marchioni M., Ratner N., DeClue J. Schwann cells from Neurofibromin-deficient mice exhibit activation of p21ras, inhibition of cell proliferation and morphologic changes. Oncogene. 11:1995;325-335.
31. M.R. Kim, F. Tamanoi, Neurofibromatosis 1 GTPase activating protein-related domain and its functional significance, in: M. Upadhyaya, D.N. Cooper (Eds.), Neurofibromatosis Type 1: From Genotype to Phenotype, BIOS Scientific Publishers, Oxford, 1998, pp. 89-112.
32. Kushner P.D., Stephanson B.A., Wright S. Reactive gliosis in the subcortical white matter of amyotrophic lateral sclerosis brain. J. Neuropathol. Exp. Neurol. 50:1991;263-277.
33. Latov N., Nilaver G., Zimmerman E.A., Johson W.G., Silverman A.J., Defendini R., Cote L. Fibrillary astrocytes proliferate in response to brain injury. Dev. Bio. 72:1979;381-384.
34. Legius E.M., Collins F.S., Glover T.W. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumor suppressor hypothesis. Nature Genet. 3:1993;122-126.
35. R.M. Lindsay, Reactive Gliosis, in: S. Fedoroff, A. Vernadakis (Eds.), Astrocytes: Cell Biology and Pathology of Astrocytes, Vol. 3, Academic Press, Orlando, FL, 1986, pp. 231-262.
36. Listernick R., Louis D.N., Packer R.J., Gutmann D.H. Optic pathways glioma in children with neurofibromatosis 1: consensus statement from the optic pathway glioma task force. Ann. Neurol. 41:1997;143-149.
37. Markwell M.A., Aaas S.M., Bieber L., Tolbert N.E. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal. Biochemistry. 82:1978;206-210.
38. Mulvihill J.J., Parry D.M., Sherman J.L., Pikus A., Kaiser-Kupfer M.I., Eldridge R. NIH conference: neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis), an update. Annals of Internal Medicine. 113:1990;39-52.
39. Nordlund M.L., Rizvi T.A., Brannan C.I., Ratner N. Neurofibromin expression and astrogliosis in neurofibromatosis (type 1) brains. J. Neuropathol. Exp. Neurology. 54:1995;588-600.
40. Nordlund M., Gu X., Shipley M.T., Ratner N. Neurofibromin is enriched in the endoplasmic reticulum of CNS neurons. J. Neurosci. 13:1993;1588-1600.
41. North K.N., Riccardi V.M., Samago-Sprouce C., Ferner R., Legius E., Moore B., Legius E., Ratner N., Denckla M.B. Cognitive function and academic performance in Neurofibromatosis type 1: consensus statement from the NF1 cognitive disorders task force. Neurology. 48:1997;1121-1127.
42. North K., Joy P., Yuille D., Cocks N., Hutchins P. Cognitive function and academic performance in children with neurofibromatosis. Develop. Medicine. Child. Neurol. 37:1995;427-436.
43. O'Callaghan J.P., Jensen K.F. Enhanced expression of glial fibrillary acidic protein and cupric silver degeneration reaction can be used as sensitive markers and early indicators of neurotoxicity. Neurotoxicology. 13:1992;113-132.
44. O'Callaghan J.P. Biochemical analysis of glial fibrillary acidic protein as a quantitative approach to neurotoxicity assessment: advantages and application to the assessment of NMDA receptor antagonist induced neurotoxicity. Psychopharmacol. Bull. 30:1994;549-554.
45. Oh T.H., Markelonis G.J., Von Visger J.R., Bail B., Shipley M.T. Acidic pH rapidly increases immunoreactivity of glial fibrillary acidic protein in cultured astrocytes. Glia. 13(4):1995;319-322.
46. Pont M.S., Elster A.D. Lesions of skin and brain: modern imaging of the neurocutaneous syndromes. Am. J. Roentgenol. 158:1992;1193-1203.
47. V.M. Riccardi, Neurofibromatosis: Phenotype, Natural History and Pathogenesis, 2nd edn., Johns Hopkins University Press, Baltimore, 1992, pp. 498.
48. Ridet J.L., Malhotra S.K., Privat A., Gage F.H. Reactive astrocytes and molecular cues to biological function. Trends Neurosci. 20(12):1997;570-577.
49. Rosenbaum T., Patrie K., Ratner N. Neurofibromatosis Type 1: genetic and cellular mechanisms of peripheral nerve tumor formation. Neuroscientist. 3:1997;412-420.
50. Rosman N.P., Pearce J. The brain in multiple neurofibromatosis (von Recklinghausen's disease): a suggested neuropathological basis for the associated mental defect. Brain. 90:1967;829-838.
51. Sevick R.J., Barkovich A.J., Edwards M.S.B., Koch T., Berg B., Lempert T. Evolution of white matter lesions in neurofibromatosis type 1: MR findings. Am. J. Roentgenol. 159:1992;171-175.
52. Shannon K.M., O'Connell P., Martin G.A., Paderanga D., Olson K., Dinndorf P., McCormick F. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. New Engl. J. Med. 330:1994;597-601.
53. Silva A.J., Frankland P.W., Marowitz Z., Friedman E., Lazlo G., Cioffi D., Jacks T., Bourtchuladze R. A mouse model for learning and memory deficits associated with neurofibromatosis type 1. Nature Genet. 15(3):1997;281-284.
54. Stone R. New marker for nerve damage. Science. 259:1993;1541.
55. Switzer C. Strategies for assessing neurotoxicity. Neurosci. Biobehav. Rev. 15:1991;89-93.
56. F.D. von Recklinghausen, Ueber die multiplen fibrome der haut und ihre Beziehung zu den multiplen Neuromen, 1882.
57. Xu W., Mulligan L.M., Ponder M.A., Liu L., Mathew C.G.P., Ponder B.A.J. Loss of Nf1 alleles in phaeochromocytomas from patients with type 1 neurofibromatosis. Genes, Chromosomes and Cancer. 4:1992;337-342.